CrossrefInfokarte
LiverPRO Reduces False Positives and Screening Costs Compared With Fibrosis-4 Index in Steatotic Liver Disease
Clinical Gastroenterology and Hepatology · 2026-11 · 24 (11) · 3148-3150
DOI: 10.1016/j.cgh.2026.01.024 ↗Abstract
Kein Abstract verfügbar.
EUVIMED